Overview

A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease

Status:
Active, not recruiting

Trial end date:
2027-12-18

Target enrollment:

Participant gender:

Summary

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

Phase:

Phase 1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Etrolizumab